| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911356 | Lung Cancer | 2012 | 5 Pages |
Abstract
Long acting somatostatin analogues could be used as an additive therapy in combination to antineoplastic agents in patients positive for somatostatin receptors. A dose of 30Â mg improved survival only in LD SCLC patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
K. Zarogoulidis, E. Eleftheriadou, Th. Kontakiotis, G. Gerasimou, P. Zarogoulidis, I. Sapardanis, G. Galaktidou, L. Sakkas, A. Gotzamani-Psarrakou, N. Karatzas,